story of the week
Durvalumab Alone and Durvalumab Plus Tremelimumab vs Chemotherapy in Patients With Metastatic Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durvalumab Alone and Durvalumab Plus Tremelimumab Versus Chemotherapy in Previously Untreated Patients With Unresectable, Locally Advanced or Metastatic Urothelial Carcinoma (DANUBE): A Randomised, Open-Label, Multicentre, Phase 3 Trial
Lancet Oncol 2020 Sep 21;[EPub Ahead of Print], T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, DP Petrylak, O Ogawa, SH Park, JL Lee, U De Giorgi, M Bögemann, A Bamias, BJ Eigl, H Gurney, SD Mukherjee, Y Fradet, I Skoneczna, M Tsiatas, A Novikov, C Suárez, AP Fay, I Duran, A Necchi, S Wildsmith, P He, N Angra, AK Gupta, W Levin, J BellmuntFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.